Efficacy and safety of pelvic floor magnetic stimulation combined with mirabegron in men with benign prostatic hyperplasia and overactive bladder in a prospective randomized controlled trial
Abstract
OBJECTIVE
This study aimed to evaluate the therapeutic efficacy and safety profile of pelvic floor magnetic stimulation (PFMS) in combination with mirabegron in male patients diagnosed with benign prostatic hyperplasia (BPH) and overactive bladder (OAB).
PATIENTS AND METHODS
Eighty-six patients were prospectively randomized into two cohorts. The control group received oral mirabegron (50 mg daily), whereas the experimental group underwent combined PFMS and mirabegron therapy. Primary endpoints included variations in urinary frequency and urgency intensity, measured through a 3-day voiding diary. Secondary endpoints included changes in the International Prostate Symptom Score (IPSS), Overactive Bladder Questionnaire (OAB-q) Health-Related Quality of Life (HRQol) index, and symptom burden, assessed at weeks 6 and 12.
RESULTS
Among the participants, 42 received the combination therapy and 44 received mirabegron monotherapy. At both time points, the combination group demonstrated significantly reduced lower urinary tract symptoms (LUTS) - including urgency, frequency, and incontinence - relative to the monotherapy group (P 0.05).
CONCLUSION
PFMS combined with mirabegron markedly alleviated BPH and OAB symptoms and improved patient-reported quality of life, without increasing the risk of adverse events compared to mirabegron monotherapy.
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design.
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.